All News

Federal agencies remain committed to increase patients' access to affordable, high quality, and comprehensive healthcare.

The study by researchers at MD Anderson Cancer Center raises the possibility of using the information provided by these dysfunctional genes.

The leaders of ACOs are working their way through a welter of immediate and longer-term issues.

With spending on diagnostics alone for cardiovascular disease likely to be a major challenge for insurers amid the baby boom wave, Aetna is turning to an emerging option as part of a strategy to avoid invasive tests and treatments.

Several cancer centers have programs in place to improve communication between PCPs and oncologists.

HHS Secretary Sylvia Mathews Burwell announced today the availability of $100 million from the Affordable Care Act to support an estimated 150 new health center sites across the country in 2015.

The Affordable Care Act (ACA) prohibits insurance companies from rejecting new customers based on their pre-existing health conditions. Yet, a recent report alleged that 4 Florida-based payers may have structured their prescription drug benefit plans in a way which does just that.

A lipid metabolite, associated with more than 70 percent of brain cancers, can help distinguish and excise cancerous tissue.

Wellness and behavioral health visits are among a few telehealth coverage expansions the CMS wants to add to the list of Medicare-reimbursable telehealth activities under a proposal released Thursday.

Over the past few decades, 38 states and the District of Columbia have switched their Medicaid plans to some form of managed care for at least part of their government programs.

Nivolumab, the first PD-1 inhibitor, was approved in Japan for treating unresectable melanoma. It has been developed in Japan by Ono Pharmaceutical, which also has rights in Korea and Taiwan.

GSK has received marketing authorization from the European Commission for trametinib as monotherapy for unresectable or metastatic melanoma in adults with a BRAF V600 mutation.

A CMS proposal would increase the number of quality measures that accountable care organizations (ACOs) would have to achieve under the Medicare Shared Savings Program in 2015.

This week, a coalition of 32 major pharmacies, health insurers, unions and pension plans asked the FDA not to require distinct names for biosimilar medications, arguing that such a move would not compromise patient safety, but could undermine the savings that are expected to be generated as these medicines are introduced into the US health care system.

The CMS intends to eliminate the exclusion for continuing medical education in the Open Payments program, more commonly known as the Sunshine Act, which requires drug and device companies to disclose payments to physicians.

Autophagy inhibition may improve cancer therapy, but it is unclear which tumors will benefit. BRAF mutations cause brain tumor cells to depend on autophagy and display selective chemosensitization with autophagy inhibition. We present a pediatric case in which deliberate autophagy inhibition halted tumor growth and overcame acquired BRAF-inhibition resistance.

The lack of OS advantage is the reason for the discontinuation.

Although some providers still operate under the traditional fee-for-service reimbursement model, that is likely to change. Payers, employers, and government agencies are increasingly choosing to reward value over volume.

Operations and maintenance, plus services segments lead growth.

Vaccination prices have gone from single digits to sometimes triple digits in the last two decades, creating dilemmas for doctors and their patients as well as straining public health budgets.

Consumers thinking about becoming enrolled in health insurance exchange plans may gain access to a new low-premium, high-deductible option: the copper plan. However, these plans have many patient advocate groups and policy experts concerned about their "bare-bone" offerings.

Despite increased spending, the breast cancer detection rate and stage did not change, according to a new JNCI study.

When new evidence emerges that a brand-name prescription drug has harmed patients, manufacturers are required to immediately warn doctors and consumers by updating product labels or sending letters.

Looking to control Medicaid costs, several states are launching accountable care initiatives that mirror experiments underway with Medicare and private insurers but vary significantly in their approaches.

It could be the first anti-PD-1 therapy in Europe, if approved.

Breakthrough Designation Reinforces Significant Unmet Need in the Treatment of This Highly Aggressive Cancer

The number of healthcare organizations participating in CMS's bundled payment program is expected to increase in upcoming weeks.

To hospitals, billions of dollars depend on how they define a patient's stay.